Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 30 Oct 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 30 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2018.
- 28 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.